US Congress Introduces BINSA Bill to Block Pharma Deals with China, Boosting Indian exporters
A bipartisan Biotech Investment National Security Act (BINSA) was filed on June 2, 2026 to expand the COINS screening list to include biotech licensing, joint ventures and technology transfers with Chinese firms. By restricting U.S. pharma collaborations with China, the bill could redirect R&D spending and drug‑supply contracts toward fast‑growing Indian manufacturers.